Literature DB >> 22007000

Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression.

Qian Wang1, Charles G Bailey, Cynthia Ng, Jessamy Tiffen, Annora Thoeng, Vineet Minhas, Melanie L Lehman, Stephen C Hendy, Grant Buchanan, Colleen C Nelson, John E J Rasko, Jeff Holst.   

Abstract

L-Type amino acid transporters such as LAT1 and LAT3 mediate the uptake of essential amino acids. Here, we report that prostate cancer cells coordinate the expression of LAT1 and LAT3 to maintain sufficient levels of leucine needed for mTORC1 signaling and cell growth. Inhibiting LAT function was sufficient to decrease cell growth and mTORC1 signaling in prostate cancer cells. These cells maintained levels of amino acid influx through androgen receptor-mediated regulation of LAT3 expression and ATF4 regulation of LAT1 expression after amino acid deprivation. These responses remained intact in primary prostate cancer, as indicated by high levels of LAT3 in primary disease, and by increased levels of LAT1 after hormone ablation and in metastatic lesions. Taken together, our results show how prostate cancer cells respond to demands for increased essential amino acids by coordinately activating amino acid transporter pathways vital for tumor outgrowth.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22007000     DOI: 10.1158/0008-5472.CAN-11-1821

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  65 in total

1.  The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability.

Authors:  Jacky Chung; Daniel E Bauer; Alireza Ghamari; Christopher P Nizzi; Kathryn M Deck; Paul D Kingsley; Yvette Y Yien; Nicholas C Huston; Caiyong Chen; Iman J Schultz; Arthur J Dalton; Johannes G Wittig; James Palis; Stuart H Orkin; Harvey F Lodish; Richard S Eisenstein; Alan B Cantor; Barry H Paw
Journal:  Sci Signal       Date:  2015-04-14       Impact factor: 8.192

2.  Overexpression of SLC7A7 predicts poor progression-free and overall survival in patients with glioblastoma.

Authors:  Songhua Fan; Delong Meng; Tao Xu; Yuanyuan Chen; Jingkun Wang; Xiaoying Li; Hongyan Chen; Daru Lu; Juxiang Chen; Qing Lan
Journal:  Med Oncol       Date:  2013-02-14       Impact factor: 3.064

Review 3.  Cross-talk between protein synthesis, energy metabolism and autophagy in cancer.

Authors:  Lisa M Lindqvist; Kristofferson Tandoc; Ivan Topisirovic; Luc Furic
Journal:  Curr Opin Genet Dev       Date:  2017-11-25       Impact factor: 5.578

Review 4.  PET Tracers Beyond FDG in Prostate Cancer.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti
Journal:  Semin Nucl Med       Date:  2016-09-07       Impact factor: 4.446

Review 5.  L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia.

Authors:  Qian Wang; Jeff Holst
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

Review 6.  Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities.

Authors:  Giorgia Zadra; Massimo Loda
Journal:  Cold Spring Harb Perspect Med       Date:  2018-10-01       Impact factor: 6.915

7.  The feasibility of assessing branched-chain amino acid metabolism in cellular models of prostate cancer with hyperpolarized [1-(13)C]-ketoisocaproate.

Authors:  Kelvin L Billingsley; Jae Mo Park; Sonal Josan; Ralph Hurd; Dirk Mayer; Eleanor Spielman-Sun; Dwight G Nishimura; James D Brooks; Daniel Spielman
Journal:  Magn Reson Imaging       Date:  2014-04-28       Impact factor: 2.546

8.  SLC Transporters: Structure, Function, and Drug Discovery.

Authors:  Claire Colas; Peter Man-Un Ung; Avner Schlessinger
Journal:  Medchemcomm       Date:  2016-03-28       Impact factor: 3.597

Review 9.  Nutrient transporters: the Achilles' heel of anabolism.

Authors:  Alison N McCracken; Aimee L Edinger
Journal:  Trends Endocrinol Metab       Date:  2013-02-08       Impact factor: 12.015

10.  Diagnostic performance of 18F-fluciclovine PET/CT in prostate cancer patients with rising PSA level ≤ 0.5 ng/ml after multiple treatment failures.

Authors:  Ajalaya Teyateeti; Achiraya Teyateeti; Gregory C Ravizzini; Guofan Xu; Chad Tang; Shi-Ming Tu; Homer A Macapinlac; Yang Lu
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.